We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+2.72%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.67B
AUM Growth
+$920K
Cap. Flow
+$82.4M
Cap. Flow %
3.09%
Top 10 Hldgs %
54.57%
Holding
76
New
9
Increased
18
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
GHRS icon
GH Research
GHRS
+$189M
2
ARGX icon
argenx
ARGX
+$97.1M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$42.5M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$34.1M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$29.8M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$239M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$61.3M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$61.3M
4
CTMX icon
CytomX Therapeutics
CTMX
+$43.1M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.39%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNCA
51
DELISTED
Genocea Biosciences, Inc.
GNCA
$9.39M 0.35%
4,012,404
– –
ELDN icon
52
Eledon Pharmaceuticals
ELDN
$261M
$8.81M 0.33%
1,113,435
– –
CDTX
53
DELISTED
Cidara Therapeutics
CDTX
$8.78M 0.33%
217,345
+30,360
+16% +$1.28M
AMRN
54
Amarin Corp
AMRN
$300M
$7.52M 0.28%
85,799
– –
RNAC icon
55
Cartesian Therapeutics
RNAC
$225M
$7.08M 0.27%
56,449
-22,884
-29% -$2.73M
RNTX
56
Rein Therapeutics
RNTX
$63M
$6.58M 0.25%
263,278
– –
VRDN icon
57
Viridian Therapeutics
VRDN
$2.1B
$6.4M 0.24%
350,081
-113,423
-24% -$1.94M
PHXM
58
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$6.38M 0.24%
131,466
+68,966
+110% +$4.26M
XFOR icon
59
X4 Pharmaceuticals
XFOR
$377M
$5.51M 0.21%
28,263
-8,123
-22% -$2.04M
GLMD icon
60
Galmed Pharmaceuticals
GLMD
$5.03M
$5.47M 0.21%
9,998
– –
EUCRU
61
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$5.09M 0.19%
500,000
– –
FLACU
62
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$5.04M 0.19%
500,000
– –
RACB
63
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$5M 0.19%
500,000
– –
FVAM
64
DELISTED
5:01 Acquisition Corp
FVAM
$4.99M 0.19%
500,000
– –
FWP
65
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$4.54M 0.17%
528,514
-118,785
-18% -$881K
JYAC
66
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.98M 0.11%
300,000
– –
RZLT icon
67
Rezolute
RZLT
$451M
$2.72M 0.1%
190,815
– –
IVA
68
Inventiva
IVA
$1.05B
$1.46M 0.05%
107,000
– –
CNTA
69
DELISTED
Centessa Pharmaceuticals
CNTA
$1.31M 0.05%
+58,900
New +$1.38M
CRNX icon
70
Crinetics Pharmaceuticals
CRNX
$8.86B
$458K 0.02%
+24,280
New +$427K
CTMX icon
71
CytomX Therapeutics
CTMX
$681M
– –
-5,576,471
Closed -$43.1M
IDYA icon
72
IDEAYA Biosciences
IDYA
$3.42B
– –
-2,607,969
Closed -$61.3M
IONS icon
73
Ionis Pharmaceuticals
IONS
$8.57B
– –
-1,364,461
Closed -$61.3M
TNGX icon
74
Tango Therapeutics
TNGX
$4.42B
– –
-800,000
Closed -$8.9M
SNCE
75
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-5,000
Closed -$1.01M
1 2
3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2021 Portfolio in Review

As of Q2 2021, BVF Inc held 76 positions worth $2.67B, up 0.03% from $2.67B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

BVF Inc deployed $82.4M of net new capital in Q2 2021, opening 9 new positions and adding to 18 existing holdings. Its largest new stake was GH Research: 9,275,156 shares worth $202M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $35.2M trimmed.

  • BVF Inc's largest Q2 2021 buy was GH Research: 9,275,156 shares worth $202M.
  • BVF Inc added most to argenx in Q2 2021, an estimated $97.1M increase.
  • BVF Inc's biggest Q2 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $35.2M.
  • BVF Inc fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $239M.
  • BVF Inc's ten largest holdings make up 55% of its $2.67B portfolio in Q2 2021.
  • BVF Inc opened 9 new positions and closed 6 in Q2 2021.
  • BVF Inc's portfolio value rose 0.03% quarter-over-quarter to $2.67B.

Based on BVF Inc's 13F filing for Q2 2021, filed 16 Aug 2021.